BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26177319)

  • 1. Parathyroid Carcinoma: Diagnosis and Clinical Implications.
    Duan K; Mete Ö
    Turk Patoloji Derg; 2015; 31 Suppl 1():80-97. PubMed ID: 26177319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological correlates of hyperparathyroidism.
    Duan K; Gomez Hernandez K; Mete O
    J Clin Pathol; 2015 Oct; 68(10):771-87. PubMed ID: 26163537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroid cancer.
    Sharretts JM; Kebebew E; Simonds WF
    Semin Oncol; 2010 Dec; 37(6):580-90. PubMed ID: 21167377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
    Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
    Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A germline mutation of HRPT2/CDC73 (70 G>T) in an adolescent female with parathyroid carcinoma: first case report and a review of the literature.
    Serrano-Gonzalez M; Shay S; Austin J; Maceri DR; Pitukcheewanont P
    J Pediatr Endocrinol Metab; 2016 Sep; 29(9):1005-12. PubMed ID: 27544721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
    Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
    J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on parathyroid carcinoma.
    Cetani F; Pardi E; Marcocci C
    J Endocrinol Invest; 2016 Jun; 39(6):595-606. PubMed ID: 27001435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity.
    Ciuffi S; Cianferotti L; Nesi G; Luzi E; Marini F; Giusti F; Zonefrati R; Gronchi G; Perigli G; Brandi ML
    Endocr J; 2019 Apr; 66(4):319-327. PubMed ID: 30799315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
    Juhlin CC; Villablanca A; Sandelin K; Haglund F; Nordenström J; Forsberg L; Bränström R; Obara T; Arnold A; Larsson C; Höög A
    Endocr Relat Cancer; 2007 Jun; 14(2):501-12. PubMed ID: 17639063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas.
    Haven CJ; van Puijenbroek M; Tan MH; Teh BT; Fleuren GJ; van Wezel T; Morreau H
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):370-6. PubMed ID: 17555500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
    Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
    Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism.
    Bricaire L; Odou MF; Cardot-Bauters C; Delemer B; North MO; Salenave S; Vezzosi D; Kuhn JM; Murat A; Caron P; Sadoul JL; Silve C; Chanson P; Barlier A; Clauser E; Porchet N; Groussin L;
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E403-8. PubMed ID: 23293331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
    Kapur A; Singh N; Mete O; Hegele RA; Fantus IG
    Endocr Pathol; 2018 Dec; 29(4):374-379. PubMed ID: 30361844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
    Hahn MA; Howell VM; Gill AJ; Clarkson A; Weaire-Buchanan G; Robinson BG; Delbridge L; Gimm O; Schmitt WD; Teh BT; Marsh DJ
    Endocr Relat Cancer; 2010 Mar; 17(1):273-82. PubMed ID: 20026646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
    Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
    J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
    Gill AJ; Lim G; Cheung VKY; Andrici J; Perry-Keene JL; Paik J; Sioson L; Clarkson A; Sheen A; Luxford C; Elston MS; Meyer-Rochow GY; Nano MT; Kruijff S; Engelsman AF; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Marsh DJ; Toon CW; Chou A; Clifton-Bligh RJ
    Am J Surg Pathol; 2019 Jan; 43(1):35-46. PubMed ID: 29324469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
    Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
    Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.
    Wang O; Wang C; Nie M; Cui Q; Guan H; Jiang Y; Li M; Xia W; Meng X; Xing X
    PLoS One; 2012; 7(9):e45567. PubMed ID: 23029104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
    Tan MH; Morrison C; Wang P; Yang X; Haven CJ; Zhang C; Zhao P; Tretiakova MS; Korpi-Hyovalti E; Burgess JR; Soo KC; Cheah WK; Cao B; Resau J; Morreau H; Teh BT
    Clin Cancer Res; 2004 Oct; 10(19):6629-37. PubMed ID: 15475453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genomic profile of parathyroid carcinoma based on whole-genome sequencing.
    Hu Y; Zhang X; Wang O; Bi Y; Xing X; Cui M; Wang M; Tao W; Liao Q; Zhao Y
    Int J Cancer; 2020 Nov; 147(9):2446-2457. PubMed ID: 32574388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.